What In Vivo Efficacy Studies Cost: Xenograft, PDX, and Syngeneic Models

How Much Does a Subcutaneous Xenograft Study Cost?

The workhorse of preclinical oncology is the subcutaneous cell line xenograft, or CDX: an established human tumor line such as HCT116, MDA-MB-231, or A549 implanted into the flank of immunodeficient mice, usually athymic nudes or NSG. For a standard design of 6-10 groups, 8-10 mice per group, and 3-6 weeks of dosing, quotes from US and EU CROs cluster between $50,000 and $150,000. That is the anchor number for xenograft study cost, and it has held fairly steady in published industry ranges through 2026.

Where you land inside that band comes down to design choices. A lean four-to-six group study with oral gavage dosing, twice-weekly caliper measurements, tumor growth inhibition (TGI) as the primary endpoint, and a summary report sits near the bottom. Add bioluminescence imaging, a PK satellite cohort with bioanalytical readouts, terminal immunohistochemistry, and a tenth dosing arm, and you will be quoting near the top of the range, sometimes past it.

A typical CDX quote covers protocol development, cell expansion and implantation, randomization once tumors reach roughly 100-200 mm³, the dosing phase, tumor and body weight measurements two or three times a week, in-life observations, necropsy with gross observations, and a data package with growth curves and statistics. Read the inclusions line by line. Two quotes that both say "8-group efficacy study" can differ by tens of thousands of dollars once you compare what each one actually delivers.

One design note that moves real money: orthotopic implantation, where tumor cells go into the organ of origin instead of the flank, adds surgical time per animal and usually forces imaging, because you cannot caliper a pancreas. Orthotopic CDX studies price meaningfully above their subcutaneous twins, so make sure the biology justifies the harder study before you sign up for it.

Why Do PDX Studies Cost Two to Three Times More?

PDX (patient-derived xenograft) models are tumor fragments taken from patients and passaged mouse to mouse, never adapted to plastic. That fidelity is the selling point, and it is also why PDX study cost runs $150,000-400,000 in typical quotes, roughly two to three times the CDX equivalent for the same number of arms.

Three things drive the premium. First, model access: most PDX models carry licensing or access fees from the CRO or an academic biobank, billed as a separate line. Second, establishment: fragments go into stock mice, get expanded through one or two passages, then get implanted into your study cohort, and randomization only happens once tumors hit volume. Every one of those steps takes weeks. Third, take rates: not every implanted fragment grows, so CROs over-implant, often materially more animals than the final design needs, and those animals are on your invoice.

Timelines follow the same logic. Expect 4-6+ months door to door including engraftment, versus 2-3 months for a CDX study, and slow-growing histologies stretch further. Budget the calendar as carefully as the dollars: a PDX readout that slips a quarter can hurt a seed-stage company more than the incremental spend does.

So when is PDX worth it? When tumor heterogeneity is the actual question you are asking, or when a partner or board wants evidence in models that track clinical response more closely. Biomarker-stratified cohorts are the other honest reason. If three well-chosen CDX lines answer your mechanism question, run those first and hold the PDX budget for the one model that matters.

What Do Syngeneic and Immuno-Oncology Studies Cost?

Syngeneic models put a mouse tumor line (CT26, MC38, 4T1, B16-F10, EMT6) into immunocompetent BALB/c or C57BL/6 mice, which makes them the default platform for immuno-oncology. Published ranges for syngeneic model cost run $60,000-180,000 per study, a step above plain CDX because of what these studies usually carry with them.

The adders are predictable. Checkpoint combination arms expand the group count fast: vehicle, anti-PD-1 alone, your agent alone, and the combination is already four groups before you touch dose levels, and reference-grade anti-PD-1 or anti-CTLA-4 antibody at combination doses is a genuine line item. Then come the immune endpoints: flow cytometry on tumor-infiltrating lymphocytes, IHC for CD8 and FoxP3, cytokine panels, sometimes tumor rechallenge in complete responders. Each is priced per sample, and samples multiply across arms.

One quirk founders miss: syngeneic tumors grow fast. CT26 and MC38 can go from implant to endpoint in three to four weeks, which compresses dosing windows and makes randomization timing unforgiving. The in-life phase is short; the analysis tail of flow panels and IHC scoring is where both the calendar and the invoice grow.

Where Do GEMMs and Humanized Mice Fit on the Price Curve?

Genetically engineered mouse models (GEMMs) sit at the top of the price curve, and most CROs will not publish a rate card for them at all. Quotes are custom because the cost lives in breeding, genotyping, colony maintenance, and tumor latency that you cannot schedule. If a GEMM cohort takes six months to develop tumors, you pay for six months of vivarium time before dosing begins.

Humanized mice, typically CD34+ hematopoietic stem cell engrafted NSG or NOG animals, are priced by the animal more than by the study. Unit costs run several multiples of a standard immunodeficient mouse, donor-to-donor variability pushes group sizes up, and immune reconstitution checks add flow cytometry work before the study proper even starts.

The practical advice: treat GEMM and humanized studies as second-generation questions. Get your first efficacy signal in CDX or syngeneic models, then spend the custom-model budget once you know exactly which question is worth a bespoke quote to answer.

What Actually Drives an In Vivo Efficacy Quote?

Every in vivo pharmacology quote is assembled from the same handful of dials, and they are the same dials that set oncology mouse model cost across vendors. Fix them in the RFQ before quotes go out.

Vendors quote the study you describe. Describe it loosely and the numbers come back spanning threefold, none of them scoped alike, and you end up reconciling inclusions instead of comparing price. Writing these choices down before the RFQ leaves your desk is the single highest-yield move a first-time buyer can make.

• Groups and arms: each added group means animals, dosing labor, and measurement time. Dose-ranging plus combination arms is how a 6-group study quietly becomes a 12-group study.
• Mice per group: 8-10 per group is standard for tumor growth inhibition endpoints; survival endpoints need larger groups and longer in-life phases.
• Dosing schedule and route: once-weekly IP is cheap; twice-daily oral gavage for six weeks is a technician-hours multiplier; IV dosing in mice carries a skill premium.
• Duration: every in-life week adds per-diems, dosing labor, and measurements across every cage on study.
• Imaging: bioluminescence (BLI) requires a luciferase-tagged line plus per-session luciferin and instrument time; MRI or microCT is priced per scan and stacks up quickly in orthotopic and metastatic models.
• PK satellites: extra animals dosed and bled for exposure confirmation, plus bioanalytical method work and sample analysis on the back end.
• Terminal endpoints: IHC, flow cytometry, tissue banking, and histopathology review each carry per-sample pricing.
• Model licensing: some cell lines and most PDX models carry access fees that appear as their own line on the quote.

How Do You Sanity-Check the Per-Arm Math?

Here is the arithmetic worth doing on the back of a term sheet. All-in per-mouse economics for outsourced efficacy work run about $300-800 per mouse in typical quotes, covering the animal, per-diems, dosing, measurements, and a share of study management. A caliper-only nude mouse study sits near the bottom of that range; an imaging-heavy NSG study with terminal endpoints sits near the top. It is the fastest gut-check on any mouse efficacy study price.

Worked example: 8 groups at 10 mice per group is 80 study animals. At $300-800 per mouse, the in-life core spans roughly $24,000-64,000. The rest of a $90,000 quote is protocol development, study direction, data analysis, statistics, and the report, plus imaging, bioanalysis, and pathology where scoped. If the implied per-mouse number on a plain subcutaneous caliper study lands well above $800, ask what you are paying for. If it lands under $300, ask what was quietly left out; usually it is the statistics, the necropsy, or the report itself.

To turn these ranges into an actual program budget, the free IND Budget Calculator builds a line-item plan across efficacy, PK, and the downstream tox package, so you can see how one PDX decision ripples through a seed-stage runway before you commit to it.

What Gets Billed as a Pass-Through, and What Carries Margin?

CRO quotes split into service fees and pass-throughs, and knowing which is which changes how you negotiate. Service fees (study direction, technical labor, report writing) carry margin and have room to move. Pass-throughs are billed at cost or cost plus a small handling fee, and arguing over them mostly burns goodwill.

Ask every vendor to break pass-throughs out explicitly in the quote. Two follow-ups worth asking: what handling percentage applies to pass-through items, and what happens to unused pass-through budget when engraftment take rates come in better than planned.

• Animals: athymic nudes are commodity-priced; NSG and NOG mice carry a real premium, and humanized animals more still.
• Compound formulation: vehicle prep usually sits inside the service fee, but non-trivial suspension or excipient work may be scoped separately or referred out as formulation development.
• Reference agents: comparator drugs and checkpoint antibodies are billed through at acquisition cost, and combination dosing burns through them fast.
• Special diets: doxycycline chow for inducible systems, alfalfa-free diets to cut autofluorescence in imaging studies.
• Imaging consumables: luciferin for BLI is a recurring per-session cost across every imaging timepoint.
• Model access fees: PDX licensing and some cell line royalties pass straight through to you.
• Shipping and import: live animal shipments and compound customs clearance, easy to forget at signing, annoying to discover on an invoice.

How Long Do These Studies Take, and How Are Extensions Priced?

Calendar time is the quiet cost. A CDX study typically runs 2-3 months door to door: two to four weeks of scheduling and cell expansion, a week or two from implant to randomization, three to six weeks of dosing, then reporting. Syngeneic studies compress the in-life phase but not the analysis. PDX runs 4-6+ months because engraftment and passaging come first. GEMMs are colony-limited and largely unschedulable, which is part of why every tumor model study price at that end of the spectrum is custom.

Extensions are where budgets drift. Studies get extended for good reasons: tumors regress and you want regrowth data, survival curves have not separated yet, or a responder cohort is worth following out. CROs price extensions per group-week or per cage-week, covering per-diems, measurements, and dosing labor if dosing continues. Get the extension rate card in writing before the study starts, because otherwise you will negotiate it mid-study with your animals on the clock.

Build decision points into the protocol up front: a pre-agreed interim look around day 21, criteria for stopping arms early, and a standing option to extend the two best-performing groups. That costs nothing to write in and saves a panicked change order later.

What Should You Ask a CRO Before Signing the Work Order?

A short list of questions separates a clean study from an expensive lesson. Ask them before you sign, not after randomization.

Then get more than one number. In vivo pharmacology cost is opaque precisely because almost nobody publishes pricing, and the spread between two credible quotes for the same design is routinely large enough to fund your PK study. BioBridgeX is a neutral marketplace built for exactly this: post your study design once, compare quotes from vetted in vivo pharmacology CROs, and contract and pay the supplier directly. It is free for buyers; suppliers pay a 2% success fee only when they are awarded the work and paid. Compare quotes once your protocol synopsis is one page long and your questions are written down: that is when the numbers you get back start to mean something.

• For PDX: what is the historical take rate for this specific model, who absorbs the cost if engraftment fails, and what are the licensing terms?
• Is imaging priced per session or bundled, and how many sessions does the plan assume?
• Who owns tissue blocks, slides, and raw imaging files at study end, and what does archiving cost?
• What is the interim data cadence: weekly tumor volume exports, or silence until the draft report?
• What is the extension rate card, per group-week, if we follow responders out?
• Which line items are pass-throughs, and at what handling percentage?
• If the compound needs formulation troubleshooting mid-study, is that scoped, hourly, or a change order?
• What happens to satellite animals and any unused mice at the end of the study?